Page last updated: 2024-12-06

quisqualic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quisqualic acid is a potent agonist of the AMPA subtype of glutamate receptors, which are essential for excitatory neurotransmission in the central nervous system. It is a natural product isolated from the seeds of the plant Quisqualis indica. Its synthesis involves a multistep process, starting from a readily available compound like 4-hydroxyquinoline. Quisqualic acid has been extensively studied for its potential to enhance cognitive function and its role in neurological disorders such as Alzheimer's disease and stroke. It has also been shown to have anti-inflammatory and neuroprotective properties. However, its use in clinical settings is limited due to its high toxicity and its rapid degradation in the body. Researchers continue to explore the potential of quisqualic acid as a pharmacological tool for understanding the role of glutamate receptors in neuronal function and for developing novel therapeutic agents.'

Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Quisqualisgenus[no description available]CombretaceaeA plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH]

Cross-References

ID SourceID
PubMed CID40539
CHEMBL ID279956
CHEMBL ID168279
CHEBI ID8734
SCHEMBL ID13319908
SCHEMBL ID136819
MeSH IDM0024938

Synonyms (85)

Synonym
MLS001074741
smr000471890
[3h]quisqualate
gtpl1370
gtpl1372
quisqualic acid, powder
NCGC00024489-01
tocris-0188
PDSP2_000801
PDSP1_000814
LOPAC0_001039
52809-07-1
quisqualic acid
C08296
qus ,
(s)-2-amino-3-(3,5-dioxo-[1,2,4]oxadiazolidin-2-yl)-propionic acid
quisqualate
DB02999
1MM6
1MM7
1P1O
NCGC00024489-04
1,2,4-oxadiazolidine-2-propanoic acid, alpha-amino-3,5-dioxo-, (s)-
c5h7n3o5
NCGC00024489-03
NCGC00024489-02
(+)-quisqualic acid
2JBK ,
2OR4 ,
quisqualate, l
chembl279956 ,
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
(2s)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
bdbm17660
NCGC00024489-05
chebi:8734 ,
2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
bdbm50164445
2-amino-3-(3,5-dioxo-[1,2,4]oxadiazolidin-2-yl)-propionic acid(quisqualic acid)
CHEMBL168279 ,
(2s)-2-azaniumyl-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoate
AC1ODZB5 ,
3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)-l-alanine
l-quisqualic acid
HMS2233G05
unii-8oc22c1b99
8oc22c1b99 ,
LP01039
.beta.-(3,5-dioxo-1,2,4-oxodiazolidin-2-yl)-l-alanine
quisqualic acid [mi]
SCHEMBL13319908
SCHEMBL136819
NCGC00261724-01
tox21_501039
(s)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
(l)-(+)-?-amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid
(l)-(+)-alpha-amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid
HB0387
AKOS024456826
mfcd00069337
sr-01000597681
SR-01000597681-1
DTXSID20896927
isopropyl3-acetylpyridine-2-carboxylate
quisqualicacid
E72650
HMS3675A13
ASNFTDCKZKHJSW-REOHCLBHSA-N
BCP13297
HMS3411A13
Q756551
NCGC00024489-07
l-quisqualic-acid
quisqualinic acid
(2s)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid.
L-210
MS-23020
HY-12597
CS-0012063
(s)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoicacid
l-alanine, 3-(3-hydroxy-5-oxo-1,2,4-oxadiazol-2(5h)-yl)-
d-quisqualic acid
52809-07-1 (l-isomer)
EN300-6498825
Z1255415656

Research Excerpts

Overview

Quisqualic acid (QA) is a potent neuroexcitant and a heterocyclic analogue of glutamate as is kainic acid. It binds to the glutamate ionotropic receptor subclass AMPA.

ExcerptReferenceRelevance
"Quisqualic acid (QA) is a potent neuroexcitant and a heterocyclic analogue of glutamate as is kainic acid. "( [Rapid hippocampal kindling following intraamygdaloid injection of quisqualic acid in cats].
Kaijima, M; Ohgami, S; Tanaka, T; Yonemasu, Y, 1983
)
1.94
"Quisqualic acid (QA) is an excitatory amino acid analogue that binds to the glutamate ionotropic receptor subclass AMPA (alpha-amino-3 hydroxy-5 methyl-4 isoxazol propionic acid) and metabotropic receptor phospholipase C. "( Quisqualic acid-induced seizures during development: a behavioral and EEG study.
Holmes, GL; Jensen, FE; Mikati, MA; Stafstrom, CE; Thurber, SJ,
)
3.02

Effects

ExcerptReferenceRelevance
"Quisqualic acid (QUIS) has been shown to interact with several glutamate receptor subtypes and uptake sites. "( Immunocytochemical evidence that quisqualate is selectively internalized into a subset of hippocampal neurons.
Beitz, AJ; Koerner, JF; Price, RH; Renno, WM; Schulte, MK, 1994
)
1.73

Toxicity

ExcerptReferenceRelevance
") were also resistant to the toxic effects of quisqualic acid, indicating the possible involvement of NMDA receptors in quisqualic acid toxicity."( Quisqualic acid-induced neurotoxicity is protected by NMDA and non-NMDA receptor antagonists.
Pai, KS; Ravindranath, V, 1992
)
1.98
" The antagonistic properties of kynurenate were dose-dependent: equimolar kynurenate had no effect on quinolinate but attenuated the actions of ibotenate, kainate and NMDA; 2 x equimolar kynurenate had no effect on quinolinate or ibotenate but attenuated the toxicity of kainate and NMDA; and 3 x equimolar kynurenate had no effect on the toxicity of kainate or ibotenate, attenuated the actions of NMDA and abolished the toxic action of quinolinate."( A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.
Clark, AJ; Hastings, MH; Latimer, M; Stone, TW; Winn, P, 1991
)
0.28
" No toxic effect of quisqualate is observed."( Kainate and NMDA toxicity for cultured developing and adult rat spiral ganglion neurons: further evidence for a glutamatergic excitatory neurotransmission at the inner hair cell synapse.
Delrée, P; Lefebvre, PP; Leprince, P; Moonen, G; Rigo, JM; Rogister, B; Weber, T, 1991
)
0.28
" Immature cortical neurons are insensitive to the toxic effects of glutamate receptor stimulation."( Glutamate toxicity in immature cortical neurons precedes development of glutamate receptor currents.
Baraban, JM; Murphy, TH, 1990
)
0.28
" The toxic potencies of glutamate, quisqualate, and homocysteate were inversely proportional to the concentration of cystine in the medium, suggesting that they competitively inhibit cystine uptake."( Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake.
Coyle, JT; Murphy, TH; Schnaar, RL, 1990
)
0.28
" When present during the exposure, 6-cyano-2,3-dihydroxy-7-nitroquinoxaline (CNQX, 10 microM), an antagonist with preferential action on non-N-methyl-D-aspartate receptors, did not prevent this toxic effect of QA."( Quisqualate neurotoxicity: a delayed, CNQX-sensitive process triggered by a CNQX-insensitive mechanism in young rat hippocampal slices.
Garthwaite, G; Garthwaite, J, 1989
)
0.28
"It has long been proposed that the excitatory and toxic properties of acidic amino acid receptor agonists are linked."( Amino acid neurotoxicity: relationship to neuronal depolarization in rat cerebellar slices.
Garthwaite, G; Garthwaite, J; Hajós, F, 1986
)
0.27
" We have investigated the receptor specificity of endogenous glutamate's toxic effects in organotypic cultures of the hippocampus by acute blockade of these transporters."( Neurotoxicity of acute glutamate transport blockade depends on coactivation of both NMDA and AMPA/Kainate receptors in organotypic hippocampal cultures.
Park, J; Tasker, RC; Vornov, JJ, 1995
)
0.29
" Micromolar concentrations of L-glutamate, as well as agonists that specifically activate N-methyl-D-aspartate (NMDA) and non-NMDA receptors, are all toxic to dopamine neurons in a concentration-dependent manner, as reflected by decreases in high-affinity dopamine uptake and confirmed by decreases in numbers of tyrosine hydroxylase-immunoreactive neurons."( Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture.
Blum, M; Casper, D, 1995
)
0.29
" In mixed cultures of cortical cells, the selective mGlu1/5 agonist, 3,5-dihydroxyphenylglycine (DHPG), amplified neurodegeneration induced by a toxic pulse of NMDA."( An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors.
Battaglia, G; Bruno, V; Ceña, V; Cespédes, VM; Copani, A; Flor, PJ; Galindo, MF; Gasparini, F; Kuhn, R; Nicoletti, F; Sánchez-Prieto, J, 2001
)
0.31
" DNQX (10 microM), an AMPA/kainate receptor antagonist, partly attenuated the toxic effects of QA, whereas LY 367 385 (100 microM), a selective mGluR1a antagonist, completely reversed the above effect."( Effects of estrone on quisqualate-induced toxicity in primary cultures of rat cortical neurons.
Kajta, M; Kubera, M; Lasoń, W; Marszał, M, 2005
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" We describe here the identification and preclinical profiling of ABP688 and its tritiated version [(3)H]ABP688, and show that its high affinity (K(d)=2nM), selectivity, and pharmacokinetic properties fulfill all requirements for development as a PET tracer for clinical imaging of the mGlu5 receptor."( ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in vitro pharmacology, pharmacokinetic and biodistribution studies.
Allgeier, H; Auberson, YP; Brülisauer, A; Gasparini, F; Hintermann, S; Hoyer, D; Lemaire, M; Moenius, T; Urwyler, S; Vranesic, I; Whitebread, S, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" The results differed as follows from those in earlier studies in which phosphoinositide turnover of the entire population of cerebellar cells was monitored: (1) the mGluR responses were not blocked by pertussis toxin or D,L-2-amino-3-phosphonopropionic acid; (2) glutamate was a potent agonist, whereas L-aspartate was ineffective; and (3) the dose-response relationship showed an all-or-none tendency."( Pharmacological and immunocytochemical characterization of metabotropic glutamate receptors in cultured Purkinje cells.
Mikoshiba, K; Yuzaki, M, 1992
)
0.28
" Dose-response measurements revealed a rank order of sensitivity to the Glu analogues in the presence of 1 microM glycine and zero extracellular Mg2+; QA greater than AMPA greater than NMDA greater than KA."( Excitatory amino acid receptors on isolated retinal ganglion cells from the goldfish.
Fain, GL; Yazejian, B, 1992
)
0.28
" The dose-response relationships of the mutant receptors were studied after expression in Xenopus oocytes by injection of the mutant alpha 1 subunit-specific mRNA together with the wild-type alpha 2-subunit-specific mRNA."( Mutations in a putative agonist binding region of the AMPA-selective glutamate receptor channel.
Mishina, M; Nagahari, K; Sakimura, K; Uchino, S, 1992
)
0.28
" An enhancing dose of La3+ shifted the dose-response curve for kainate to lower concentrations of agonist without changing the maximum evoked current, and a similar leftward shift of the quisqualate dose-response curve occurred at non-saturating concentrations of quisqualate."( Lanthanum actions on excitatory amino acid-gated currents and voltage-gated calcium currents in rat dorsal horn neurons.
MacDermott, AB; Reichling, DB, 1991
)
0.28
" L-Aspartate (L-Asp) produced a similar dose-response relationship."( Electrogenic uptake contributes a major component of the depolarizing action of L-glutamate in rat hippocampal slices.
Blake, JF; Brown, MW; Collingridge, GL; Frenguelli, BG, 1991
)
0.28
" This is observed as a shift to the right in the NMDA dose-response curves for both the positive and negative postsynaptic components of the evoked tectal response."( Chronic application of NMDA decreases the NMDA sensitivity of the evoked tectal potential in the frog.
Cline, HT; Constantine-Paton, M; Debski, EA; McDonald, JW, 1991
)
0.28
" 200 microM guanosine triphosphate (GTP) produced a decrease of 50% in L-[3H]glutamate binding activity and competition experiments produced an affinity shift to the right of the glutamate dose-response curve."( Characterization of L-[3H]glutamate binding sites in bovine brain coated vesicles.
Cubero, A; González-Calero, G; Martín, M, 1991
)
0.28
" In the presence of 10 microM KA, the dose-response curve of QU became biphasic, whereas with 50 microM KA, a reduction of the response was seen around 1-100 microM QU."( Interactions of glutamate receptor agonists coupled to changes in intracellular Ca2+ in rat cerebellar granule cells in primary culture.
Akerman, KE; Holopainen, I; Louve, M, 1991
)
0.28
" Injection of oocytes with both the mRNAs produces current responses larger than those induced by the GluR1-specific mRNA and the dose-response relations indicate a positively cooperative interaction between the two subunits."( Functional expression from cloned cDNAs of glutamate receptor species responsive to kainate and quisqualate.
Araki, K; Bujo, H; Kushiya, E; Meguro, H; Mishina, M; Numa, S; Sakimura, K; Warashina, A; Yamazaki, M, 1990
)
0.28
" Dose-response curves obtained in oocytes were bell shaped, with a negative slope for high concentrations of QA."( Reduction of desensitization of a glutamate ionotropic receptor by antagonists.
Audinat, E; Crepel, F; Geoffroy, M; Hamon, B; Kado, RT; Lambolez, B; Rossier, J, 1991
)
0.28
" Additionally, the overlap of the dose-response curves for activation of the steady-state current and desensitization of the peak current by a conditioning dose suggests that the two processes are related."( Characterization of quisqualate receptor desensitization in cultured postnatal rat hippocampal neurons.
Clifford, DB; Thio, LL; Zorumski, CF, 1991
)
0.28
" Analyses of dose-response curves of these inward currents indicate that both the QA and KA currents were competitively blocked by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), while the NMDA current was blocked non-competitively."( Glutamate receptor agonist-induced inward currents in spinal dorsal horn neurons dissociated from the adult rats.
Arancio, O; MacDermott, AB; Murase, K; Yoshimura, M, 1991
)
0.28
" The results suggest that 1) the insult to cholinergic neurons in the NBM may be involved in the PA memory consolidation deficit induced by nonselective quisqualic acid lesioning; 2) the beneficial effects of THA on NBM lesion-induced PA retention deficit occur in a narrow dose range; 3) the alleviating effects of THA on NBM lesion-induced PA memory deficits are blocked by frontal cortex lesions; and 4) the dose-response window for THA-induced PA retention performance improvement is broadened by repeated treatment."( Effects of THA on passive avoidance retention performance of intact, nucleus basalis, frontal cortex and nucleus basalis + frontal cortex-lesioned rats.
Riekkinen, M; Riekkinen, P; Sirviö, J, 1991
)
0.48
" The dose-response relationship of quisqualate acting at the N-methyl-D-aspartate (NMDA) receptor was measured as that portion of the whole-cell current activated by quisqualate that could be blocked by the addition of two NMDA antagonists, 5-fluoroindole-2-carboxylic acid, a competitive antagonist of the NMDA receptor-associated glycine site, and D-2-amino-5-phosphonovalerate, a competitive NMDA binding site antagonist."( Quisqualate activates N-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture.
Grudt, TJ; Jahr, CE, 1990
)
0.28
" Neither drug effected seizures in control rats, however, both GDEE and MK-801 produced a leftward shift in the strychnine-seizure dose-response curve in 3AP inferior olive-lesioned rats."( The effects of inferior olive lesion on strychnine seizure.
Anderson, MC; Chung, EY; Van Woert, MH, 1990
)
0.28
"25 and 200 mumol/kg as revealed by the dose-response curves obtained in both experiments."( NMDA antagonist properties of gamma-L-glutamyl-L-aspartate demonstrated on chemically induced seizures in mice.
De Barry, J; Mathis, C; Ungerer, A, 1990
)
0.28
" Although the dose-response curve is hyperbolic with an ED50 of 78 microM, glutamate apparently activates 2 types of receptors on motoneurons."( Characterization of excitatory amino acid receptors expressed by embryonic chick motoneurons in vitro.
Fischbach, GD; O'Brien, RJ, 1986
)
0.27
" With increasing ketamine concentration (5 x 10(-5)-10(-3) mol l-1), the amplitude of glutamate potentials was reduced and dose-response curves for ionophoresis of L-glutamate were shifted to the right, particularly after concanavalin A treatment."( Enhancement of desensitization of quisqualate-type glutamate receptor by the dissociative anaesthetic ketamine.
Ashford, ML; Boden, P; Ramsey, RL; Usherwood, PN, 1989
)
0.28
" KA-activated currents (I(KA)) differ from QA-activated currents (I(QA)) in their dose-response characteristics, desensitization patterns, selective blockade with kynurenic acid and suppression by elevated [Ca2+]o, I(KA), but not I(QA), is significantly reduced by low levels of [Cl-]o, and the [Cl-]o-dependent shift of the reversal potential for I(KA) suggests that KA promotes a conductance decrease for Cl-."( Separation of quisqualate- and kainate-selective glutamate receptors in cultured neurons from the rat superior colliculus.
Grantyn, R; Perouansky, M, 1989
)
0.28
" At a concentration of 10 microM, CNQX reversibly antagonized responses to alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualate and kainate; it produced a parallel shift in their log dose-response curves."( 6-Cyano-7-nitroquinoxaline-2,3-dione as an excitatory amino acid antagonist in area CA1 of rat hippocampus.
Blake, JF; Brown, MW; Collingridge, GL; Yates, RG, 1989
)
0.28
" Their respective dose-response curves had a similar maximum but the slope of the curve for AMPA was consistently steeper than that for quisqualate."( The pharmacology of quisqualate and AMPA in the cerebral cortex of the rat in vitro.
Horne, AL; Simmonds, MA, 1989
)
0.28
" In this preparation, all these antagonists shifted the NMDA dose-response curve to the right in a parallel manner."( Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex.
Harrison, NL; Simmonds, MA, 1985
)
0.27
" Analysis of iontophoretic dose-response curves indicated that DL-APV was a competitive antagonist."( Action of excitatory amino acids and their antagonists on hippocampal neurons.
Hablitz, JJ, 1985
)
0.27
" This dose-response curve of L-Glu was shifted to the left in the presence of D-Asp, although the maximal amount of release was unchanged."( Effects of D-aspartate on excitatory amino acid-induced release of [3H]GABA from goldfish retina.
Cha, JH; Dowling, JE; O'Brien, DR, 1986
)
0.27
" We found that excitatory amino acid agonists evoked somatostatin release in the following order of potency: quisqualate greater than glutamate = N-methyl-D-aspartate (NMDA) greater than kainate, as calculated from the dose-response curves."( Glutamate stimulates somatostatin release from diencephalic neurons in primary culture.
Astier, H; Tapia-Arancibia, L, 1988
)
0.27
" The dose-response relationship of EAA (N-methyl-D-aspartate (NMDA), kainate, quisqualate and glutamate)-induced activation revealed qualitative and quantitative differences in their pattern of action, suggesting that these agonists act at distinct receptors."( Behavioral classification of excitatory amino acid receptors in mouse spinal cord.
Raigorodsky, G; Urca, G, 1988
)
0.27
" Dose-response analysis reveals that the AA-gated cation conductance activated by kainate requires the binding of two agonist molecules."( Properties of two classes of rat brain acidic amino acid receptors induced by distinct mRNA populations in Xenopus oocytes.
Davidson, N; Fong, TM; Lester, HA, 1988
)
0.27
" Dose-response curves and IC50 values were determined for these antagonists against all four agonists."( The action of quinolinate in the rat spinal cord in vitro.
Curry, K; Magnuson, DS; McLennan, H; Peet, MJ, 1987
)
0.27
" When the amount of quisqualate which was simultaneously applied with glutamate was changed, the amplitudes of the maximum response of glutamate plus quisqualate did not vary much at the top of the dose-response curves."( Quisqualate action on the crayfish neuromuscular junction.
Ishida, M; Shinozaki, H, 1981
)
0.26
" In the present experiments, the selective sigma ligands DTG, (+)pentazocine, BD-737, JO-1784 and L-687,384 were studied to determine if they would also generate bell-shaped dose-response curves."( Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate.
Bergeron, R; de Montigny, C; Debonnel, G, 1995
)
0.29
" Cyclothiazide increased the maximum response to a saturating concentration of kainate by approximately 300% and produced a shift to the left in the kainate dose-response curve."( Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate.
Mayer, ML; Patneau, DK; Vyklicky, L, 1993
)
0.29
" Dose-response curves for inhibition of [3H]CNQX by AMPA and kainate were biphasic."( Autoradiographic characterization of the non-N-methyl-D-aspartate binding sites in human cerebellum using the antagonist [3H]6-cyano-7-nitroquinoxaline-2,3-dione.
Hatziefthimiou, A; Kouvelas, ED; Mitsacos, A, 1994
)
0.29
" Further characterization of the dose-response effects of the compounds on quisqualate induced [Ca2+]i mobilization showed that although the magnitude of phenylglycine inhibition was reduced for both mGluR subtypes compared to those observed for stimulation of PI hydrolysis (except for 4C3HPG on mGluR1 alpha), similar differences in the relative potencies of the phenylglycines between mGluR1 alpha (IC50s: 40 +/- 10 microM for 4C3HPG: 300-1000 microM for 4CPG and M4CPG) and mGluR5a (IC50s: > 1000 microM) were evident."( Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes.
Burnett, JP; Kingston, AE; Lodge, D; Mayne, NG, 1995
)
0.29
" Prolonged infusion of very small amounts of DCG-IV showed a bell-shaped dose-response relationship with regard to protection against kainate-induced neurotoxicity."( [Pharmacology of the glutamate receptor].
Shinozaki, H, 2000
)
0.31
" Dose-response analyses revealed that mgl-2 has approximately a 15-20-fold lower affinity for glutamate and quisqualate compared to rat mGluR5."( Orthosteric and allosteric drug binding sites in the Caenorhabditis elegans mgl-2 metabotropic glutamate receptor.
Burns, AR; Hampson, DR; Roy, PJ; Tharmalingam, S, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (79)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00350.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency3.98110.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.97630.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency44.66840.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.15080.100020.879379.4328AID488773; AID588453; AID588456
phosphopantetheinyl transferaseBacillus subtilisPotency66.89670.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency2.99350.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency0.01000.02827.055915.8489AID895; AID928
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.01190.28189.721235.4813AID2326
arylsulfatase AHomo sapiens (human)Potency23.93411.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency12.58930.039816.784239.8107AID995
DNA polymerase kappa isoform 1Homo sapiens (human)Potency1.00000.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.00000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency0.79430.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01780.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutamate Receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.02000.02000.0200AID977608
Chain A, Glutamate Receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.02000.02000.02000.0200AID977608
Metabotropic glutamate receptor 6Homo sapiens (human)Ki1,000.00000.40002.50005.8000AID107093
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)5.10000.00011.617910.0000AID92490; AID92507
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)5.10000.00011.700010.0000AID92490; AID92507
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)5.10000.00011.700010.0000AID92490; AID92507
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)5.10000.00011.700010.0000AID92490; AID92507
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)IC50 (µMol)0.15000.00700.98217.0000AID93711
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)Ki0.17040.00071.71758.1800AID339927
Metabotropic glutamate receptor 1Rattus norvegicus (Norway rat)Ki0.01000.00790.31450.9000AID108493
Glutamate receptor 1Mus musculus (house mouse)IC50 (µMol)0.08000.04000.75502.3000AID92048
Glutamate receptor 2Mus musculus (house mouse)IC50 (µMol)0.08000.04000.75502.3000AID92048
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.600310.0000AID145038
Metabotropic glutamate receptor 5Homo sapiens (human)Ki0.05500.00050.54638.2000AID107059
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)IC50 (µMol)0.15000.00701.01327.0000AID93711
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)Ki0.13290.00370.80254.1000AID339928
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)IC50 (µMol)0.15000.00701.01327.0000AID93711
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Ki1.52520.00380.79754.1000AID339929
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.630610.0000AID145038
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00061.525710.0000AID145038
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.747210.0000AID145038
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)IC50 (µMol)0.15000.00701.01327.0000AID93711
Glutamate carboxypeptidase 2Homo sapiens (human)IC50 (µMol)9.50000.00030.83169.5000AID1797641; AID291424
Metabotropic glutamate receptor 1Homo sapiens (human)Ki1.10000.00033.536310.0000AID108489
Metabotropic glutamate receptor 2Homo sapiens (human)Ki556.50000.00270.71586.4000AID108830; AID108837
Metabotropic glutamate receptor 3Homo sapiens (human)Ki40.00000.00130.61549.0000AID109164
Metabotropic glutamate receptor 4Homo sapiens (human)Ki556.00000.16001.15672.4000AID109341; AID109463
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID145038
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)IC50 (µMol)0.15000.00701.01327.0000AID93711
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID145038
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00071.741110.0000AID145038
Cystine/glutamate transporterHomo sapiens (human)IC50 (µMol)5.00000.14001.14005.0000AID475922
Glutamate receptor 4Mus musculus (house mouse)IC50 (µMol)0.08000.04000.75502.3000AID92048
Glutamate receptor 3Mus musculus (house mouse)IC50 (µMol)0.08000.04000.75502.3000AID92048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutamate receptor 2Rattus norvegicus (Norway rat)Kd1.74000.16004.900012.8000AID977611
Chain A, Glutamate receptor 2Rattus norvegicus (Norway rat)Kd1.74000.16004.900012.8000AID977611
Chain C, Glutamate receptor 2Rattus norvegicus (Norway rat)Kd1.74000.16004.900012.8000AID977611
Metabotropic glutamate receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)4.11000.20004.494610.0000AID108352; AID108498; AID108499; AID108500
Metabotropic glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)750.00000.00061.42627.7000AID108845
Metabotropic glutamate receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)40.00000.00211.89099.0000AID109170
Metabotropic glutamate receptor 4Rattus norvegicus (Norway rat)EC50 (µMol)109.66670.00902.54409.4900AID109466; AID246705
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)EC50 (µMol)0.23330.00151.653710.0000AID107063; AID107064
Metabotropic glutamate receptor 6Rattus norvegicus (Norway rat)EC50 (µMol)1,000.00000.05502.40307.6000AID107240
Metabotropic glutamate receptor 7Rattus norvegicus (Norway rat)EC50 (µMol)1,000.00000.14600.82301.5000AID107263
Metabotropic glutamate receptor 5Homo sapiens (human)EC50 (µMol)0.39000.00190.61454.1000AID109493; AID1573527
Metabotropic glutamate receptor 8Mus musculus (house mouse)EC50 (µMol)100.00000.02200.21100.4000AID107403
Metabotropic glutamate receptor 1Homo sapiens (human)EC50 (µMol)0.20000.20004.41009.3000AID108648
Metabotropic glutamate receptor 2Homo sapiens (human)EC50 (µMol)1,000.00000.00061.17848.5000AID108677
Metabotropic glutamate receptor 7Homo sapiens (human)EC50 (µMol)1,000.00000.15850.66921.1800AID107260
Metabotropic glutamate receptor 4Homo sapiens (human)EC50 (µMol)500.00000.00401.71939.8000AID109333
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 6Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 6Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 6Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 6Homo sapiens (human)
detection of visible lightMetabotropic glutamate receptor 6Homo sapiens (human)
detection of light stimulus involved in visual perceptionMetabotropic glutamate receptor 6Homo sapiens (human)
retina development in camera-type eyeMetabotropic glutamate receptor 6Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 6Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of DNA-templated transcriptionMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
phospholipase C-activating G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
learning or memoryMetabotropic glutamate receptor 5Homo sapiens (human)
learningMetabotropic glutamate receptor 5Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMetabotropic glutamate receptor 5Homo sapiens (human)
synapse organizationMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of calcium-mediated signalingMetabotropic glutamate receptor 5Homo sapiens (human)
cognitionMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
cellular response to amyloid-betaMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 5Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
proteolysisGlutamate carboxypeptidase 2Homo sapiens (human)
folic acid-containing compound metabolic processGlutamate carboxypeptidase 2Homo sapiens (human)
C-terminal protein deglutamylationGlutamate carboxypeptidase 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 1Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 1Homo sapiens (human)
sensory perception of painMetabotropic glutamate receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of sensory perception of painMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 1Homo sapiens (human)
cellular response to electrical stimulusMetabotropic glutamate receptor 1Homo sapiens (human)
L-glutamate import across plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 1Homo sapiens (human)
negative regulation of adenylate cyclase activityMetabotropic glutamate receptor 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 2Homo sapiens (human)
gene expressionMetabotropic glutamate receptor 2Homo sapiens (human)
glutamate secretionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of glutamate secretionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of dopamine secretionMetabotropic glutamate receptor 2Homo sapiens (human)
behavioral response to nicotineMetabotropic glutamate receptor 2Homo sapiens (human)
response to cocaineMetabotropic glutamate receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMetabotropic glutamate receptor 2Homo sapiens (human)
long-term synaptic depressionMetabotropic glutamate receptor 2Homo sapiens (human)
intracellular glutamate homeostasisMetabotropic glutamate receptor 2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of response to drugMetabotropic glutamate receptor 2Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 2Homo sapiens (human)
behavioral fear responseMetabotropic glutamate receptor 7Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 7Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 7Homo sapiens (human)
sensory perception of soundMetabotropic glutamate receptor 7Homo sapiens (human)
negative regulation of glutamate secretionMetabotropic glutamate receptor 7Homo sapiens (human)
axon developmentMetabotropic glutamate receptor 7Homo sapiens (human)
glycosylationMetabotropic glutamate receptor 7Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 7Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 7Homo sapiens (human)
negative regulation of adenylate cyclase activityMetabotropic glutamate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 3Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 3Homo sapiens (human)
gene expressionMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMetabotropic glutamate receptor 3Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 3Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 4Homo sapiens (human)
neurotransmitter secretionMetabotropic glutamate receptor 4Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of neuron apoptotic processMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 4Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
glutathione metabolic processCystine/glutamate transporterHomo sapiens (human)
visual learningCystine/glutamate transporterHomo sapiens (human)
response to toxic substanceCystine/glutamate transporterHomo sapiens (human)
response to organic cyclic compoundCystine/glutamate transporterHomo sapiens (human)
L-cystine transportCystine/glutamate transporterHomo sapiens (human)
L-glutamate transmembrane transportCystine/glutamate transporterHomo sapiens (human)
ventricular system developmentCystine/glutamate transporterHomo sapiens (human)
striatum developmentCystine/glutamate transporterHomo sapiens (human)
adult behaviorCystine/glutamate transporterHomo sapiens (human)
regulation of neutrophil apoptotic processCystine/glutamate transporterHomo sapiens (human)
cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
glutathione transmembrane transportCystine/glutamate transporterHomo sapiens (human)
response to nicotineCystine/glutamate transporterHomo sapiens (human)
regulation of cell population proliferationCystine/glutamate transporterHomo sapiens (human)
regulation of melanin biosynthetic processCystine/glutamate transporterHomo sapiens (human)
lung alveolus developmentCystine/glutamate transporterHomo sapiens (human)
modulation of chemical synaptic transmissionCystine/glutamate transporterHomo sapiens (human)
regulation of synapse organizationCystine/glutamate transporterHomo sapiens (human)
regulation of protein transportCystine/glutamate transporterHomo sapiens (human)
response to redox stateCystine/glutamate transporterHomo sapiens (human)
limb developmentCystine/glutamate transporterHomo sapiens (human)
lens fiber cell differentiationCystine/glutamate transporterHomo sapiens (human)
platelet aggregationCystine/glutamate transporterHomo sapiens (human)
intracellular glutamate homeostasisCystine/glutamate transporterHomo sapiens (human)
L-glutamate import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
negative regulation of ferroptosisCystine/glutamate transporterHomo sapiens (human)
dipeptide import across plasma membraneCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transportCystine/glutamate transporterHomo sapiens (human)
regulation of cellular response to oxidative stressCystine/glutamate transporterHomo sapiens (human)
regulation of cysteine metabolic processCystine/glutamate transporterHomo sapiens (human)
regulation of glutathione biosynthetic processCystine/glutamate transporterHomo sapiens (human)
regulation of AMPA glutamate receptor clusteringCystine/glutamate transporterHomo sapiens (human)
regulation of glutamate metabolic processCystine/glutamate transporterHomo sapiens (human)
amino acid transmembrane transportCystine/glutamate transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 6Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
protein homodimerization activityMetabotropic glutamate receptor 6Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 6Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase activator activityMetabotropic glutamate receptor 5Homo sapiens (human)
A2A adenosine receptor bindingMetabotropic glutamate receptor 5Homo sapiens (human)
identical protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase bindingMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled receptor activity involved in regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
metallocarboxypeptidase activityGlutamate carboxypeptidase 2Homo sapiens (human)
peptidase activityGlutamate carboxypeptidase 2Homo sapiens (human)
dipeptidase activityGlutamate carboxypeptidase 2Homo sapiens (human)
metal ion bindingGlutamate carboxypeptidase 2Homo sapiens (human)
Ac-Asp-Glu bindingGlutamate carboxypeptidase 2Homo sapiens (human)
tetrahydrofolyl-poly(glutamate) polymer bindingGlutamate carboxypeptidase 2Homo sapiens (human)
carboxypeptidase activityGlutamate carboxypeptidase 2Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 1Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor activity involved in regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
calcium channel regulator activityMetabotropic glutamate receptor 2Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 2Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
scaffold protein bindingMetabotropic glutamate receptor 2Homo sapiens (human)
group II metabotropic glutamate receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
group III metabotropic glutamate receptor activityMetabotropic glutamate receptor 7Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 7Homo sapiens (human)
adenylate cyclase inhibitor activityMetabotropic glutamate receptor 7Homo sapiens (human)
protein dimerization activityMetabotropic glutamate receptor 7Homo sapiens (human)
serine bindingMetabotropic glutamate receptor 7Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
calcium channel regulator activityMetabotropic glutamate receptor 3Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
scaffold protein bindingMetabotropic glutamate receptor 3Homo sapiens (human)
group II metabotropic glutamate receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
protein bindingCystine/glutamate transporterHomo sapiens (human)
cystine:glutamate antiporter activityCystine/glutamate transporterHomo sapiens (human)
L-kynurenine transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
L-amino acid transmembrane transporter activityCystine/glutamate transporterHomo sapiens (human)
protein bindingGlutamate receptor 4Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
Golgi membraneMetabotropic glutamate receptor 6Homo sapiens (human)
endoplasmic reticulum membraneMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
dendriteMetabotropic glutamate receptor 6Homo sapiens (human)
new growing cell tipMetabotropic glutamate receptor 6Homo sapiens (human)
synapseMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneMetabotropic glutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneMetabotropic glutamate receptor 4Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
dendriteMetabotropic glutamate receptor 5Homo sapiens (human)
cytoplasmMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic spineMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic shaftMetabotropic glutamate receptor 5Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 5Homo sapiens (human)
Schaffer collateral - CA1 synapseMetabotropic glutamate receptor 5Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 5Homo sapiens (human)
postsynaptic density membraneMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
cytoplasmGlutamate carboxypeptidase 2Homo sapiens (human)
plasma membraneGlutamate carboxypeptidase 2Homo sapiens (human)
cell surfaceGlutamate carboxypeptidase 2Homo sapiens (human)
membraneGlutamate carboxypeptidase 2Homo sapiens (human)
extracellular exosomeGlutamate carboxypeptidase 2Homo sapiens (human)
plasma membraneGlutamate carboxypeptidase 2Homo sapiens (human)
nucleusMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
dendriteMetabotropic glutamate receptor 1Homo sapiens (human)
Schaffer collateral - CA1 synapseMetabotropic glutamate receptor 1Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor dimeric complexMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor homodimeric complexMetabotropic glutamate receptor 1Homo sapiens (human)
postsynaptic density membraneMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 2Homo sapiens (human)
axonMetabotropic glutamate receptor 2Homo sapiens (human)
dendriteMetabotropic glutamate receptor 2Homo sapiens (human)
presynaptic membraneMetabotropic glutamate receptor 2Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 2Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 2Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 2Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 7Homo sapiens (human)
cell cortexMetabotropic glutamate receptor 7Homo sapiens (human)
membraneMetabotropic glutamate receptor 7Homo sapiens (human)
axonMetabotropic glutamate receptor 7Homo sapiens (human)
dendriteMetabotropic glutamate receptor 7Homo sapiens (human)
asymmetric synapseMetabotropic glutamate receptor 7Homo sapiens (human)
dendritic shaftMetabotropic glutamate receptor 7Homo sapiens (human)
postsynaptic membraneMetabotropic glutamate receptor 7Homo sapiens (human)
presynaptic active zoneMetabotropic glutamate receptor 7Homo sapiens (human)
receptor complexMetabotropic glutamate receptor 7Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 7Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic densityMetabotropic glutamate receptor 3Homo sapiens (human)
axonMetabotropic glutamate receptor 3Homo sapiens (human)
presynaptic membraneMetabotropic glutamate receptor 3Homo sapiens (human)
dendritic spineMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic membraneMetabotropic glutamate receptor 3Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 3Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 3Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 3Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
cytoplasmic vesicleMetabotropic glutamate receptor 4Homo sapiens (human)
presynapseMetabotropic glutamate receptor 4Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneCystine/glutamate transporterHomo sapiens (human)
cell surfaceCystine/glutamate transporterHomo sapiens (human)
membraneCystine/glutamate transporterHomo sapiens (human)
brush border membraneCystine/glutamate transporterHomo sapiens (human)
microvillus membraneCystine/glutamate transporterHomo sapiens (human)
apical part of cellCystine/glutamate transporterHomo sapiens (human)
astrocyte projectionCystine/glutamate transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (113)

Assay IDTitleYearJournalArticle
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID180312Inhibitory concentration against evoked synaptic field potential of CA1 neurons in absence of quisqualic acid from rat hippocampus1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site.
AID190589Sensitization effect was determined1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site.
AID180313Inhibitory concentration against evoked synaptic field potential of CA1 neurons in presence of 16 uM quisqualic acid from rat hippocampus1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site.
AID246705Stimulation of [3H]phosphatidylinositol accumulation by rat Metabotropic glutamate receptor 4 co-expressed with Gqi9 protein in HEK 293 cells; Inactive2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4.
AID205942Repolarization time for compound was measured by pattern firing by APN and KVN blockade1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis, resolution, and absolute configuration of the isomers of the neuronal excitant 1-amino-1,3-cyclopentanedicarboxylic acid.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2002Biochemistry, Dec-31, Volume: 41, Issue:52
Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate.
AID1811Experimentally measured binding affinity data derived from PDB2002Biochemistry, Dec-31, Volume: 41, Issue:52
Mechanism of activation and selectivity in a ligand-gated ion channel: structural and functional studies of GluR2 and quisqualate.
AID1346254Rat mGlu5 receptor (Metabotropic glutamate receptors)2000Journal of neurochemistry, Dec, Volume: 75, Issue:6
Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.
AID1346276Rat mGlu1 receptor (Metabotropic glutamate receptors)2000Journal of neurochemistry, Dec, Volume: 75, Issue:6
Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections.
AID1346863Human Cystine/glutamate transporter (SLC7 family)2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter.
AID1346276Rat mGlu1 receptor (Metabotropic glutamate receptors)2003Molecular pharmacology, May, Volume: 63, Issue:5
[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID108648Effective concentration for half maximal stimulation of PI hydrolysis (mGluR1a)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists.
AID175680Effective concentration by measuring IP2 accumulation using rat fore brain synaptoneurosomes1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and biological activity of glutamic acid derivatives.
AID42538ability to directly depolarize CA1 pyramidal neurons of rat hyppocampal slices after exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID42540ability to directly depolarize CA1 pyramidal neurons of rat hyppocampal slices before exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID339927Displacement of [3H]SYM2081 from rat recombinant iGluR52008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.
AID109466Concentration for half maximal activation of metabotropic glutamate mGluR4a in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID107260Concentration for half maximal activation of metabotropic glutamate mGluR7 in human1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID175679Effective concentration by measuring IP1 accumulation using rat fore brain synaptoneurosomes1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and biological activity of glutamic acid derivatives.
AID231225Potency at metabotropic glutamate receptor 4, measured as the ratio of EC50 to IC502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID108500Concentration for half maximal activation of metabotropic glutamate mGluR1c in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID108677Concentration for half maximal activation of metabotropic glutamate mGluR2 in human1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID108493Inhibition of binding to rat mGluR1a (metabotropic glutamate receptor) expressed in HEK-293 cells2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID42546sensitization of CA1 pyramidal neurons to depolarizations by L-AP6 before exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID107240Concentration for half maximal activation of metabotropic glutamate mGluR6 in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID180121Inhibition of the sensitization of CA1 pyramidal neurons to depolarization by L-AP6 by the compound at a concentration of 16 uM after 4 minutes1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Cyclobutane quisqualic acid analogues as selective mGluR5a metabotropic glutamic acid receptor ligands.
AID109341Agonist potency against cloned human Metabotropic glutamate receptor 4 (mGluR-4)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID92490Inhibition of Ionotropic glutamate receptor AMPA mediated depolarization by the compound at a concentration of 16 uM after 4 minutes1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Cyclobutane quisqualic acid analogues as selective mGluR5a metabotropic glutamic acid receptor ligands.
AID179872Emax by measuring IP1 accumulation using rat fore brain synaptoneurosomes1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and biological activity of glutamic acid derivatives.
AID108343In vitro binding affinity against Metabotropic glutamate receptor using [3H](S)-glutamic acid1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid.
AID179873Emax by measuring IP2 accumulation using rat fore brain synaptoneurosomes1998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Synthesis and biological activity of glutamic acid derivatives.
AID107403Concentration for half maximal activation of metabotropic glutamate mGluR8 in mouse1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID180120Inhibition of the sensitization of CA1 pyramidal neurons to depolarization by L-AP6 after reversal with L-alpha-AA by the compound at a concentration of 16 uM after 4 minutes1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Cyclobutane quisqualic acid analogues as selective mGluR5a metabotropic glutamic acid receptor ligands.
AID109493Concentration for half maximal activation of metabotropic glutamate mGluR5a in human1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID231223Potency at metabotropic glutamate receptor 1, measured as the ratio of EC50 to IC502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID93711Compound was tested or its affinity against ionotropic glutamate receptor ionotropic kainate in rats1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID475922Inhibition of amino acid transport system xc-2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter.
AID107093Agonist potency against cloned Metabotropic glutamate receptor 6 (mGluR-6).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID108499Concentration for half maximal activation of metabotropic glutamate mGluR1b in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID107063Concentration for half maximal activation of metabotropic glutamate mGluR5a in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID1573527Agonist activity at mGlu5 receptor (unknown origin) expressed in CHO cells assessed as increase in Gq-mediated PI hydrolysis after 45 mins by yttrium scintillation proximity assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID42545sensitization of CA1 pyramidal neurons to depolarizations by L-AP6 after reversal with L-alpha-AA1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID25808Ionization constant was determined1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Excitatory amino acid neurotransmission.
AID108506Ratio between EC50 of compound and glutamate measured against metabotropic glutamate receptor 11999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Agonist selectivity of mGluR1 and mGluR2 metabotropic receptors: a different environment but similar recognition of an extended glutamate conformation.
AID108830Agonist potency against cloned Metabotropic glutamate receptor 2 (mGluR-2).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID339929Displacement of [3H]SYM2081 from rat recombinant iGluR72008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.
AID108498Concentration for half maximal activation of metabotropic glutamate mGluR1a in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID108837Binding affinity at Metabotropic glutamate receptor 22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID156919Inhibition of specific brain peptidase1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Excitatory amino acid neurotransmission.
AID92041Percent control measured by evaluating the inhibition of 3 nM [125I]PhTX-343-lysine binding to glutamate receptors in rat cortical membranes1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and binding of [125I2]philanthotoxin-343, [125I2]philanthotoxin-343-lysine, and [125I2]philanthotoxin-343-arginine to rat brain membranes.
AID92507The compound was tested for its affinity against AMPA receptor in rats1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID108352Concentration for half maximal activation of metabotropic glutamate mGluR1b in human1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID107263Concentration for half maximal activation of metabotropic glutamate mGluR7 in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID108845Concentration for half maximal activation of metabotropic glutamate mGluR2 in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID291424Inhibition of human recombinant glutamate carboxypeptidase 2 by radioenzymatic assay2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
AID196574Compound was tested for electrophysiological experiments using rat cortical wedge preparation1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid.
AID339928Displacement of [3H]SYM2081 from rat recombinant iGluR62008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.
AID109333Concentration for half maximal activation of metabotropic glutamate mGluR4a in human1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID42544sensitization of CA1 pyramidal neurons to depolarizations by L-AP6 after exposure to quisqualic acid1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID108985Ratio between EC50 of compound and glutamate measured against Metabotropic glutamate receptor 21999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Agonist selectivity of mGluR1 and mGluR2 metabotropic receptors: a different environment but similar recognition of an extended glutamate conformation.
AID109164Agonist potency against cloned Metabotropic glutamate receptor 3 (mGluR-3).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID108489Agonist potency against cloned human metabotropic glutamate receptor 12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID109170Concentration for half maximal activation of metabotropic glutamate mGluR3 in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID231224Potency at metabotropic glutamate receptor 2, measured as the ratio of EC50 to IC502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID180122Inhibition of the sensitization of CA1 pyramidal neurons to depolarization by L-AP6 by the compound at a concentration of 16 uM before 4 minutes1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Cyclobutane quisqualic acid analogues as selective mGluR5a metabotropic glutamic acid receptor ligands.
AID75015The effective concentration for 50% glutamate response was measured on Group I Metabotropic glutamate receptor1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Pharmacophore models of group I and group II metabotropic glutamate receptor agonists. Analysis of conformational, steric, and topological parameters affecting potency and selectivity.
AID75021The effective concentration for 50% glutamate response was measured on Group II Metabotropic glutamate receptor1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Pharmacophore models of group I and group II metabotropic glutamate receptor agonists. Analysis of conformational, steric, and topological parameters affecting potency and selectivity.
AID92048Compound was tested for in vitro binding affinity against Ionotropic glutamate receptor AMPA using [3H]AMPA ligand1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid.
AID109463Binding affinity at Metabotropic glutamate receptor 42002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Common and selective molecular determinants involved in metabotopic glutamate receptor agonist activity.
AID107059Agonist potency against cloned metabotropic glutamate receptor 52000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID107064Concentration for half maximal activation of metabotropic glutamate mGluR5b in rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Metabotropic glutamate receptors: novel targets for drug development.
AID145038Inhibition of [3H]CPP binding to rat N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.
AID42539ability to directly depolarize CA1 pyramidal neurons of rat hyppocampal slices after reversal with L-alpha-AA1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Synthesis of oxadiazolidinedione derivatives as quisqualic acid analogues and their evaluation at a quisqualate-sensitized site in the rat hippocampus.
AID1811Experimentally measured binding affinity data derived from PDB2003Proceedings of the National Academy of Sciences of the United States of America, May-13, Volume: 100, Issue:10
Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2003Proceedings of the National Academy of Sciences of the United States of America, May-13, Volume: 100, Issue:10
Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1346276Rat mGlu1 receptor (Metabotropic glutamate receptors)2003The Journal of biological chemistry, Mar-07, Volume: 278, Issue:10
Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1797641Determination of Inhibition Concentration Values (IC50) from Article 10.1021/jm070133w: \\Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.\\2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,327)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990376 (28.33)18.7374
1990's766 (57.72)18.2507
2000's139 (10.47)29.6817
2010's38 (2.86)24.3611
2020's8 (0.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.03 (24.57)
Research Supply Index7.22 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews24 (1.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1,338 (98.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]